Department of Gynecologic Oncology and Reproductive Medicine and the Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Corresponding author: Michael Frumovitz, MD, MPH, Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; email: [email protected].

Financial Disclosure Michael Frumovitz reports receiving payments from Stryker and Seagen. Anil K. Sood reports receiving payment from GSK, Merck, and Onxeo. He has been a consultant for Iylon, Kiyatec, and ImmunoGen. He is also a shareholder in BioPath (intellectual property [EGFL6 antibodies licensed to Top Alliance]). The other authors did not report any potential conflicts of interest.

The authors thank Stephanie Deming, Research Medical Library, MD Anderson Cancer Center, for editing the manuscript.

Each author has confirmed compliance with the journal's requirements for authorship.

Peer reviews and author correspondence are available at https://links.lww.com/AOG/D109.